Skandinaviska Enskilda Banken (SEB)’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.17M | Hold |
340,267
| – | – | 0.01% | 636 |
|
|
2025
Q1 | $759K | Hold |
340,267
| – | – | ﹤0.01% | 665 |
|
|
2024
Q4 | $960K | Hold |
340,267
| – | – | ﹤0.01% | 660 |
|
|
2024
Q3 | $885K | Buy |
340,267
+31,700
| +10% | +$82.4K | ﹤0.01% | 682 |
|
|
2024
Q2 | $913K | Buy |
308,567
+158,000
| +105% | +$468K | ﹤0.01% | 648 |
|
|
2024
Q1 | $682K | Buy |
150,567
+59,200
| +65% | +$268K | ﹤0.01% | 688 |
|
|
2023
Q4 | $522K | Buy |
91,367
+7,500
| +9% | +$42.8K | ﹤0.01% | 775 |
|
|
2023
Q3 | $386K | Buy |
83,867
+3,000
| +4% | +$13.8K | ﹤0.01% | 787 |
|
|
2023
Q2 | $522K | Buy |
+80,867
| New | +$522K | ﹤0.01% | 785 |
|
|
2021
Q2 | – | Sell |
-65,000
| Closed | -$2.23M | – | 1042 |
|
|
2021
Q1 | $2.23M | Buy |
+65,000
| New | +$2.23M | 0.01% | 625 |
|